Syndax Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Syndax Pharmaceuticals, Inc. (SNDX) had Additional Paid in Capital, Common Stock of $1.61 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital, Common Stock $1.61B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.59B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.57B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.55B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.61B 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.59B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $1.57B 10-Q · filed 2026-08-04 |
| 2025-09-30 | $1.55B 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.53B 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.52B 10-Q · filed 2025-05-05 |
| 2024-12-31 | $1.51B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.49B 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.48B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.47B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.46B 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.19B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.18B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.17B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.16B 10-K · filed 2024-02-27 |
| 2022-09-30 | $993.55M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $981.71M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $956.05M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $952.02M 10-K · filed 2023-02-28 |
| 2021-09-30 | $838.89M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $833.80M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $824.54M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $820.82M 10-K · filed 2022-03-01 |
| 2020-09-30 | $680.13M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $675.29M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $564.16M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $527.07M 10-K · filed 2021-03-12 |
| 2019-09-30 | $525.49M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $523.86M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $522.34M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $492.49M 10-K · filed 2020-03-05 |
| 2018-06-30 | $473.69M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $472.03M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $470.57M 10-K · filed 2019-03-07 |
| 2017-09-30 | $443.69M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $441.22M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $390.89M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $389.37M 10-K · filed 2018-03-08 |
| 2016-09-30 | $388.21M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $385.56M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $384.77M 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |